Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neuroprotective effects of <scp>PPAR</scp>‐γ agonist rosiglitazone in N171‐82Q mouse model of Huntington's disease

4 Feb 2013

Abstract excerpt

Huntington's disease (HD) is a devastating genetic neurodegenerative disease caused by CAG trinucleotide expansion in the exon-1 region of the huntingtin gene. Currently, no cure is available. It is becoming increasingly apparent that mutant Huntingtin (HTT) impairs metabolic homeostasis and causes transcriptional dysregulation. The peroxisome proliferator-activated receptor gamma (PPAR-γ) is a transcriptional...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adipose Tissue and Metabolism
Share to Genetic Neurodegenerative Diseases
Share to Mitochondrial Function and Pathology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23373812
DOI: 10.1111/jnc.12190

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neuroprotective effects of <scp>PPAR</scp>‐γ agonist rosiglitazone in N171‐82Q mouse model of Huntington's diseasePMID 23373812Read ↗

Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease.Semantic proximity Read ↗

Pioglitazone suppresses neuronal and muscular degeneration caused by polyglutamine-expanded androgen receptorsSemantic proximity Read ↗

Pharmacological upregulation of PGC1α in oligodendrocytes: implications for Huntington's Disease.Semantic proximity Read ↗

Glitazones, PPAR-γ and NeuroprotectionSemantic proximity Read ↗

Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease.Semantic proximity Read ↗

PPARgamma rescue of the mitochondrial dysfunction in Huntington's diseaseSemantic proximity Read ↗

PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeuticallySemantic proximity Read ↗

PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disordersSemantic proximity Read ↗

GLP-1 Analogue Liraglutide Attenuates Mutant Huntingtin-Induced Neurotoxicity by Restoration of Neuronal Insulin SignalingSemantic proximity Read ↗

PPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer's disease.Semantic proximity Read ↗

The neuroprotective effects of α7 nicotinic acetylcholine receptor against mutant copper-zinc superoxide dismutase 1-mediated toxicitySemantic proximity Read ↗

The Role of PGC1α in Alzheimer’s Disease and Therapeutic InterventionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.